The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Insights into the CARTITUDE-6 trial: rationale and design
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some insights into the CARTITUDE-6 trial (NCT05257083), which will evaluate the combination of daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel (cilta-cel) versus DVRd followed by autologous stem cell transplant (autoSCT) in the frontline setting. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
